Edmund Silins1, L John Horwood2, George C Patton3, David M Fergusson2, Craig A Olsson4, Delyse M Hutchinson5, Elizabeth Spry6, John W Toumbourou7, Louisa Degenhardt8, Wendy Swift5, Carolyn Coffey6, Robert J Tait9, Primrose Letcher10, Jan Copeland11, Richard P Mattick5. 1. National Drug and Alcohol Research Centre, UNSW Australia, Sydney, NSW, Australia. Electronic address: e.silins@unsw.edu.au. 2. Christchurch Health and Development Study, Department of Psychological Medicine, University of Otago, Christchurch, New Zealand. 3. Centre for Adolescent Health, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia. 4. Centre for Adolescent Health, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia; School of Psychology, Deakin University, Geelong, VIC, Australia; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia; Psychological Sciences, University of Melbourne, Melbourne, VIC, Australia. 5. National Drug and Alcohol Research Centre, UNSW Australia, Sydney, NSW, Australia. 6. Centre for Adolescent Health, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia. 7. Centre for Adolescent Health, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia; School of Psychology, Deakin University, Geelong, VIC, Australia. 8. National Drug and Alcohol Research Centre, UNSW Australia, Sydney, NSW, Australia; Centre for Adolescent Health, Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia; School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia; Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA. 9. National Drug Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA, Australia; Centre for Research on Ageing Health and Wellbeing, Australian National University, Canberra, ACT, Australia. 10. Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia. 11. National Cannabis Prevention and Information Centre, UNSW Australia, Sydney, NSW, Australia.
Abstract
BACKGROUND: Debate continues about the consequences of adolescent cannabis use. Existing data are limited in statistical power to examine rarer outcomes and less common, heavier patterns of cannabis use than those already investigated; furthermore, evidence has a piecemeal approach to reporting of young adult sequelae. We aimed to provide a broad picture of the psychosocial sequelae of adolescent cannabis use. METHODS: We integrated participant-level data from three large, long-running longitudinal studies from Australia and New Zealand: the Australian Temperament Project, the Christchurch Health and Development Study, and the Victorian Adolescent Health Cohort Study. We investigated the association between the maximum frequency of cannabis use before age 17 years (never, less than monthly, monthly or more, weekly or more, or daily) and seven developmental outcomes assessed up to age 30 years (high-school completion, attainment of university degree, cannabis dependence, use of other illicit drugs, suicide attempt, depression, and welfare dependence). The number of participants varied by outcome (N=2537 to N=3765). FINDINGS: We recorded clear and consistent associations and dose-response relations between the frequency of adolescent cannabis use and all adverse young adult outcomes. After covariate adjustment, compared with individuals who had never used cannabis, those who were daily users before age 17 years had clear reductions in the odds of high-school completion (adjusted odds ratio 0·37, 95% CI 0·20-0·66) and degree attainment (0·38, 0·22-0·66), and substantially increased odds of later cannabis dependence (17·95, 9·44-34·12), use of other illicit drugs (7·80, 4·46-13·63), and suicide attempt (6·83, 2·04-22·90). INTERPRETATION: Adverse sequelae of adolescent cannabis use are wide ranging and extend into young adulthood. Prevention or delay of cannabis use in adolescence is likely to have broad health and social benefits. Efforts to reform cannabis legislation should be carefully assessed to ensure they reduce adolescent cannabis use and prevent potentially adverse developmental effects. FUNDING: Australian Government National Health and Medical Research Council.
BACKGROUND: Debate continues about the consequences of adolescent cannabis use. Existing data are limited in statistical power to examine rarer outcomes and less common, heavier patterns of cannabis use than those already investigated; furthermore, evidence has a piecemeal approach to reporting of young adult sequelae. We aimed to provide a broad picture of the psychosocial sequelae of adolescent cannabis use. METHODS: We integrated participant-level data from three large, long-running longitudinal studies from Australia and New Zealand: the Australian Temperament Project, the Christchurch Health and Development Study, and the Victorian Adolescent Health Cohort Study. We investigated the association between the maximum frequency of cannabis use before age 17 years (never, less than monthly, monthly or more, weekly or more, or daily) and seven developmental outcomes assessed up to age 30 years (high-school completion, attainment of university degree, cannabis dependence, use of other illicit drugs, suicide attempt, depression, and welfare dependence). The number of participants varied by outcome (N=2537 to N=3765). FINDINGS: We recorded clear and consistent associations and dose-response relations between the frequency of adolescent cannabis use and all adverse young adult outcomes. After covariate adjustment, compared with individuals who had never used cannabis, those who were daily users before age 17 years had clear reductions in the odds of high-school completion (adjusted odds ratio 0·37, 95% CI 0·20-0·66) and degree attainment (0·38, 0·22-0·66), and substantially increased odds of later cannabis dependence (17·95, 9·44-34·12), use of other illicit drugs (7·80, 4·46-13·63), and suicide attempt (6·83, 2·04-22·90). INTERPRETATION: Adverse sequelae of adolescent cannabis use are wide ranging and extend into young adulthood. Prevention or delay of cannabis use in adolescence is likely to have broad health and social benefits. Efforts to reform cannabis legislation should be carefully assessed to ensure they reduce adolescent cannabis use and prevent potentially adverse developmental effects. FUNDING: Australian Government National Health and Medical Research Council.
Authors: Jonathan D Schaefer; Nayla R Hamdi; Stephen M Malone; Scott Vrieze; Sylia Wilson; Matt McGue; William G Iacono Journal: Proc Natl Acad Sci U S A Date: 2021-04-06 Impact factor: 11.205
Authors: Benedikt Fischer; Cayley Russell; Pamela Sabioni; Wim van den Brink; Bernard Le Foll; Wayne Hall; Jürgen Rehm; Robin Room Journal: Am J Public Health Date: 2017-06-23 Impact factor: 9.308
Authors: Natalie Castellanos-Ryan; Jean-Baptiste Pingault; Sophie Parent; Frank Vitaro; Richard E Tremblay; Jean R Séguin Journal: Dev Psychopathol Date: 2016-12-29
Authors: Andrea H Weinberger; Lauren R Pacek; Melanie M Wall; Michael J Zvolensky; Jan Copeland; Sandro Galea; Shadi Nahvi; Scott J Moeller; Deborah S Hasin; Renee D Goodwin Journal: Drug Alcohol Depend Date: 2018-07-20 Impact factor: 4.492
Authors: Douglas Bruce; Alida M Bouris; Shannon Bowers; Olivia Blocker; Soo Young Lee; Mary F Glidden; John A Schneider; Daniel H Reirden Journal: Addict Res Theory Date: 2019-06-26